8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 29, 2020

NuVasive, Inc.

(Exact name of registrant as specified in its charter)

Delaware	000-50744	33-0768598
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)
7475 Lusk Boulevard, San Diego, California 92121
(Address of principal executive offices) (Zip Code)
(858) 909-1800
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	NUVA	The NASDAQ Stock Market LLC (NASDAQ Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

  Item 2.02   Results of Operations and Financial Condition.

On October 29, 2020, NuVasive, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2020. A copy of this press release is furnished as Exhibit 99.1 to this Current Report.

Item 7.01 Regulation FD Disclosure.

During a conference call scheduled to be held at 1:30 p.m. Pacific Time on October 29, 2020, the Company’s Chief Executive Officer and Chief Financial Officer will discuss the Company’s results for the quarter ended September 30, 2020.

The information contained in this Current Report and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01	Financial Statements and Exhibits.
(d)	Exhibits.
Exhibit No.	Description
99.1	Press Release issued by NuVasive, Inc. on October 29, 2020
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NUVASIVE, INC.
Date: October 29, 2020	/s/ Matthew K. Harbaugh
	Matthew K. Harbaugh
	Executive Vice President and Chief Financial Officer

EX-99.1

Exhibit 99.1

NEWS RELEASE

NuVasive Announces Third Quarter 2020 Financial Results

SAN DIEGO – October 29, 2020 – NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended September 30, 2020.

Third Quarter 2020 Highlights

• Net sales increased 1.5% to $295.3 million, or 1.2% on a constant currency basis;

• GAAP operating margin of 9.2%; Non-GAAP operating margin of 15.8%; and

• GAAP diluted earnings per share of $0.11; Non-GAAP diluted earnings per share of $0.55.

“In the third quarter, NuVasive experienced faster-than-anticipated recovery from the impact of COVID-19 with net sales increasing year over year driven by high-single digit growth in our International business and further stability of the US spine market,” said J. Christopher Barry, chief executive officer of NuVasive. “The Company remains focused in the fourth quarter on executing against its innovation roadmap, including the launch of our re-designed cervical portfolio, the furthering of our Advanced Materials Science implant portfolio with multiple new implants and executing on key Pulse milestones.”

A full reconciliation of GAAP to non-GAAP financial measures can be found in the tables of this news release. NuVasive announced in April 2020 that it had withdrawn its annual financial guidance due to the uncertainty related to COVID-19, and is not reinstituting its annual financial guidance for the remainder of the year.

Third Quarter 2020 Results

NuVasive reported third quarter 2020 total net sales of $295.3 million, a 1.5% increase compared to $290.8 million for the third quarter 2019. On a constant currency basis, third quarter 2020 total net sales increased 1.2% compared to the same period last year.

For the third quarter 2020, both GAAP and non-GAAP gross profit was $210.6 million and GAAP and non-GAAP gross margin was 71.3%. These results compared to GAAP and non-GAAP gross profit of $213.8 million and GAAP and non-GAAP gross margin of 73.5%, for the third quarter 2019.

The Company reported GAAP net income of $5.9 million, or diluted earnings per share of $0.11, for the third quarter 2020, compared to GAAP net income of $11.0 million, or diluted earnings per share of $0.21, for the third quarter 2019. On a non-GAAP basis, the Company reported net income of $28.3 million, or diluted earnings per share of $0.55, for the third quarter 2020, compared to non-GAAP net income of $30.9 million, or diluted earnings per share of $0.59, for the third quarter 2019.

The Company ended the quarter with $982.1 million in cash and cash equivalents, and short term investments.

Supplementary Financial Information

For additional financial detail, please visit the Investor Relations section of the Company's website at www.nuvasive.com to access Supplementary Financial Information.

Reconciliation of GAAP to Non-GAAP Information

Management uses certain non-GAAP financial measures such as non-GAAP diluted earnings per share, non-GAAP net income, non-GAAP operating expenses and non-GAAP operating margin, which exclude amortization of intangible assets, business transition costs, purchased in-process research and development, one-time restructuring and related items in connection with acquisitions, investments and divestitures, non-recurring consulting fees, certain litigation expenses and settlements, certain European medical device regulation costs, gains and losses from strategic investments, gains and losses from changes in fair value of derivatives and non-cash interest expense (excluding debt issuance cost). Management also uses certain non-GAAP measures which are intended to exclude the impact of foreign exchange currency fluctuations. The measure constant currency utilizes an exchange rate that eliminates fluctuations when calculating financial performance numbers. The Company also uses measures such as free cash flow, which represents cash flow from operations less cash used in the acquisition and disposition of capital. Additionally, the Company uses an adjusted EBITDA measure which represents earnings before interest, taxes, depreciation and amortization and excludes the impact of stock-based compensation, business transition costs, purchased in-process research and development, one-time restructuring and related items in connection with acquisitions, investments and divestitures, non-recurring consulting fees, certain litigation expenses and settlements, certain European medical device regulation costs, gains and losses on strategic investments, gains and losses from changes in fair value of derivatives and other significant one-time items.

Management calculates the non-GAAP financial measures provided in this earnings release excluding these costs and uses these non-GAAP financial measures to enable it to further and more consistently analyze the period-to-period financial performance of its core business operations. Management believes that providing investors with these non-GAAP measures gives them additional information to enable them to assess, in the same way management assesses, the Company's current and future continuing operations. These non-GAAP measures are not in accordance with, or an alternative for, GAAP, and may be different from non-GAAP measures used by other companies. Set forth below are reconciliations of the non-GAAP financial measures to the comparable GAAP financial measure.

	For the Three Months Ended September 30, 2020
	Reconciliation of GAAP to Non-GAAP Financial Measures
	(Unaudited - in thousands, except per share data)
		Gross Profit			Operating Profit			Net Income			Diluted EPS		Diluted WASO5		Net Income to Adjusted EBITDA
	Reported GAAP	$	210,649		$	27,052		$	5,872		$	0.11		51,805	$	5,872
	% of revenue		71.3	%		9.2	%
	Amortization of intangible assets					13,826			13,826
	Litigation related expenses and settlements1					1,396			1,396							1,396
	Business transition costs2					3,107			3,107							3,107
	European medical device regulation3					1,149			1,149							1,149
	Non-cash interest expense on convertible notes								12,683
	Net gain on strategic investments								(1,132	)						(1,132	)
	Tax effect of adjustments4								(8,575	)
	Interest expense/(income), net															20,852
	Income tax expense															579
	Depreciation and amortization															35,959
	Non-cash stock-based compensation															7,572
	Adjusted Non-GAAP	$	210,649		$	46,530		$	28,326		$	0.55		51,805	$	75,354
	% of revenue		71.3	%		15.8	%									25.5	%
1	Represents expenses associated with certain ongoing litigation matters, including infringement of the Company’s intellectual property.
2	Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs, contingent consideration fair value adjustments, and other costs directly associated with such activities.
3	Represents costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with European medical device regulation.
4	Represents the impact from tax affecting the adjustments above at their statutory tax rate.
5	Adjusted non-GAAP diluted WASO excludes the impact of all dilutive securities, including convertible notes for which the Company is economically hedged through its anti-dilutive bond hedge arrangements.

	For the Nine Months Ended September 30, 2020
	Reconciliation of GAAP to Non-GAAP Financial Measures
	(Unaudited - in thousands, except per share data)
		Gross Profit			Operating Profit			Net (Loss) Income			Diluted EPS			Diluted WASO7		Net (Loss) to Adjusted EBITDA
	Reported GAAP	$	521,772		$	18,068		$	(38,845	)	$	(0.76	)		51,440	$	(38,845	)
	% of revenue		68.8	%		2.4	%
	Amortization of intangible assets					39,150			39,150
	Litigation related expenses and settlements1					5,686			5,686								5,686
	Business transition costs2					2,541			2,541								2,541
	Purchase of in-process research and development3					1,011			1,011								1,011
	European medical device regulation4					4,079			4,079								4,079
	Non-cash interest expense on convertible notes								28,022
	Net loss on strategic investments								278								278
	Net loss recognized on change in fair value of derivatives5								12,301								12,301
	Tax effect of adjustments6								(20,834	)
	Interest expense/(income), net																47,858
	Income tax benefit																(9,764	)
	Depreciation and amortization																106,097
	Non-cash stock-based compensation																9,751
	Adjusted Non-GAAP	$	521,772		$	70,535		$	33,389		$	0.64			52,033	$	140,993
	% of revenue		68.8	%		9.3	%										18.6	%
1	Represents expenses associated with certain ongoing litigation matters, including infringement of the Company’s intellectual property.
2	Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs, contingent consideration fair value adjustments, and other costs directly associated with such activities.
3	Purchase of an in-process research and development asset which had no future alternative use.
4	Represents costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with European medical device regulation.
5	Represents the net change in fair value of the Company’s derivative asset and liability associated with the 2023 Notes.
6	Represents the impact from tax affecting the adjustments above at their statutory tax rate.
7	Adjusted non-GAAP diluted WASO excludes the impact of dilutive convertible notes for which the Company is economically hedged through its anti-dilutive bond hedge arrangements.

	For the Three Months Ended September 30, 2019
	Reconciliation of GAAP to Non-GAAP Financial Measures
	(Unaudited - in thousands, except per share data)
		Gross Profit			Operating Profit			Net Income			Diluted EPS		Diluted WASO5		Net Income to Adjusted EBITDA
	Reported GAAP	$	213,807		$	30,514		$	11,010		$	0.21		53,056	$	11,010
	% of revenue		73.5	%		10.5	%
	Amortization of intangible assets					12,596			12,596
	Litigation related expenses and settlements1					1,899			1,899							1,899
	Business transition costs2					(333	)		(333	)						(333	)
	European medical device regulation3					953			953							953
	Non-cash interest expense on convertible notes								4,432
	Net loss on strategic investments								4,767							4,767
	Tax effect of adjustments4								(4,455	)
	Interest expense/(income), net															9,034
	Income tax expense															4,774
	Depreciation and amortization															33,631
	Non-cash stock-based compensation															7,829
	Adjusted Non-GAAP	$	213,807		$	45,629		$	30,869		$	0.59		52,590	$	73,564
	% of revenue		73.5	%		15.7	%									25.3	%
1	Represents expenses associated with certain ongoing litigation matters, including infringement of the Company’s intellectual property.
2	Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs, contingent consideration fair value adjustments, and other costs directly associated with such activities.
3	Represents costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with European medical device regulation.
4	Represents the impact from tax affecting the adjustments above at their statutory tax rate. As of October 30, 2019, the Company estimated an annual tax rate of ~26% on a GAAP basis and ~23% on a non-GAAP basis.
5	Adjusted non-GAAP diluted WASO excludes the impact of dilutive convertible notes for which the Company is economically hedged through its anti-dilutive bond hedge arrangements.

	For the Nine Months Ended September 30, 2019
	Reconciliation of GAAP to Non-GAAP Financial Measures
	(Unaudited - in thousands, except per share data)
		Gross Profit			Operating Profit			Net Income			Diluted EPS		Diluted WASO5		Net Income to Adjusted EBITDA
	Reported GAAP	$	628,615		$	80,884		$	35,358		$	0.67		52,667	$	35,358
	% of revenue		73.3	%		9.4	%
	Amortization of intangible assets					38,498			38,498
	Litigation related expenses and settlements1					6,976			6,976							6,976
	Business transition costs2					5,146			5,146							5,146
	European medical device regulation3					2,685			2,685							2,685
	Non-cash interest expense on convertible notes								13,125
	Net loss on strategic investments								4,767							4,767
	Tax effect of adjustments4								(15,269	)
	Interest expense/(income), net															27,461
	Income tax expense															12,012
	Depreciation and amortization															101,245
	Non-cash stock-based compensation															20,447
	Adjusted Non-GAAP	$	628,615		$	134,189		$	91,286		$	1.74		52,512	$	216,097
	% of revenue		73.3	%		15.6	%									25.2	%
1	Represents expenses associated with certain ongoing litigation matters, including infringement of the Company’s intellectual property.
2	Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs, contingent consideration fair value adjustments, and other costs directly associated with such activities.
3	Represents costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with European medical device regulation.
4	Represents the impact from tax affecting the adjustments above at their statutory tax rate. As of October 30, 2019, the Company estimated an annual tax rate of ~26% on a GAAP basis and ~23% on a non-GAAP basis.
5	Adjusted non-GAAP diluted WASO excludes the impact of dilutive convertible notes for which the Company is economically hedged through its anti-dilutive bond hedge arrangements.

Investor Conference Call

NuVasive will hold a conference call today at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results of its financial performance for the third quarter 2020. The dial-in numbers are 1-877-407-9039 for domestic callers and 1-201-689-8470 for international callers. A live webcast of the conference call will be available online from the Investor Relations page of the Company's website at www.nuvasive.com. After the live webcast, the call will remain available on NuVasive's website through November 29, 2020. In addition, a telephone replay of the call will be available until November 5, 2020. The replay dial-in numbers are 1-844-512-2921 for domestic callers and 1-412-317-6671 for international callers. Please use pin number: 13708396.

About NuVasive

NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care and change lives. The Company's less invasive, procedurally integrated surgical solutions are designed to deliver reproducible and clinically proven outcomes. The Company’s comprehensive procedural portfolio includes access, implants and fixation systems, biologics, software for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With more than $1 billion in net sales, NuVasive has approximately 2,800 employees and operates in more than 50 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.

Forward-Looking Statements

NuVasive cautions you that statements included in this news release or made on the investor conference call referenced herein that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. In addition, this news release contains selected financial results from the third quarter 2020. The Company’s results for the third quarter 2020 are prior to the completion of review and audit procedures by the Company’s external auditors and are subject to adjustment. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, the impact of the COVID-19 pandemic on the Company's business and financial results; the Company’s ability to maintain operations to support its customers and patients in the near-term and to capitalize on future growth opportunities; risks associated with acceptance of the Company's surgical products and procedures by spine surgeons and hospitals, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products, the Company's ability to adequately manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties more fully described in the Company’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

NuVasive, Inc.
Consolidated Statements of Operations
(in thousands, except per share data)
	Three Months Ended September 30,						Nine Months Ended September 30,
(unaudited)	2020			2019			2020			2019
Net sales:
Products	$	267,571		$	260,173		$	685,922		$	765,377
Services		27,711			30,662			72,853			92,339
Total net sales		295,282			290,835			758,775			857,716
Cost of sales (excluding below amortization of intangible assets):
Products		66,049			57,164			182,067			169,263
Services		18,584			19,864			54,936			59,838
Total cost of sales		84,633			77,028			237,003			229,101
Gross profit		210,649			213,807			521,772			628,615
Operating expenses:
Selling, general and administrative		146,260			152,887			402,935			450,816
Research and development		20,404			18,143			58,067			53,271
Amortization of intangible assets		13,826			12,596			39,150			38,498
Purchase of in-process research and development		—			—			1,011			—
Business transition costs		3,107			(333	)		2,541			5,146
Total operating expenses		183,597			183,293			503,704			547,731
Interest and other expense, net:
Interest income		271			620			1,306			1,356
Interest expense		(21,123	)		(9,654	)		(49,164	)		(28,817	)
Other income (expense), net		251			(5,696	)		(18,819	)		(6,053	)
Total interest and other expense, net		(20,601	)		(14,730	)		(66,677	)		(33,514	)
Income (loss) before income taxes		6,451			15,784			(48,609	)		47,370
Income tax (expense) benefit		(579	)		(4,774	)		9,764			(12,012	)
Consolidated net income (loss)	$	5,872		$	11,010		$	(38,845	)	$	35,358
Net income (loss) per share:
Basic	$	0.11		$	0.21		$	(0.76	)	$	0.68
Diluted	$	0.11		$	0.21		$	(0.76	)	$	0.67
Weighted average shares outstanding:
Basic		51,261			52,057			51,440			51,901
Diluted		51,805			53,056			51,440			52,667

NuVasive, Inc.
Consolidated Balance Sheets
(in thousands, except par values and share amounts)
	September 30, 2020			December 31, 2019
ASSETS	(Unaudited)
Current assets:
Cash and cash equivalents	$	774,544		$	213,034
Short-term marketable securities		207,605			—
Accounts receivable, net of allowances of $20,924 and $17,019, respectively		205,255			211,532
Inventory, net		305,634			312,419
Prepaid income taxes		13,322			10,434
Prepaid expenses and other current assets		15,576			16,917
Total current assets		1,521,936			764,336
Property and equipment, net		281,339			266,318
Intangible assets, net		165,499			201,092
Goodwill		558,985			561,064
Operating lease right-of-use assets		103,994			66,932
Deferred tax assets		9,291			9,162
Restricted cash and investments		1,494			1,494
Other assets		14,033			14,892
Total assets	$	2,656,571		$	1,885,290
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable and accrued liabilities	$	112,392		$	97,160
Contingent consideration liabilities		7,275			15,727
Accrued payroll and related expenses		53,005			86,458
Operating lease liabilities		7,513			5,567
Income tax liabilities		760			2,005
Senior convertible notes		639,682			—
Total current liabilities		820,627			206,917
Long-term senior convertible notes		756,167			623,298
Deferred and income tax liabilities		8,236			14,655
Operating lease liabilities		113,105			73,153
Other long-term liabilities		48,734			52,060
Commitments and contingencies
Redeemable equity component of senior convertible notes		10,318			—
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized, none outstanding		—			—
Common stock, $0.001 par value; 150,000,000 and 120,000,000 shares authorized at September 30, 2020 and December 31, 2019, respectively; 57,813,261 and 57,524,658 issued and outstanding at September 30, 2020 and December 31, 2019, respectively		62			62
Additional paid-in capital		1,533,409			1,429,854
Accumulated other comprehensive loss		(10,152	)		(9,418	)
Retained earnings		43,630			82,475
Treasury stock at cost; 6,540,526 shares and 5,379,536 shares at September 30, 2020 and December 31, 2019, respectively		(667,565	)		(587,766	)
Total equity		899,384			915,207
Total liabilities and equity	$	2,656,571		$	1,885,290

NuVasive, Inc.
Consolidated Statements of Cash Flows
(in thousands)
	Nine Months Ended September 30,
(unaudited)	2020			2019
Operating activities:
Consolidated net (loss) income	$	(38,845	)	$	35,358
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization		106,097			101,245
Amortization of non-cash interest		33,714			15,853
Stock-based compensation		9,806			20,447
Reserves on current assets		44,927			11,539
Purchase of in-process research and development		1,011			—
Net loss on strategic investments		278			4,767
Net loss recognized on change in fair value of derivatives		12,301			—
Other non-cash adjustments		13,899			10,168
Deferred income taxes		(6,257	)		9,810
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable		2,388			(8,645	)
Inventory		(37,523	)		(45,571	)
Prepaid expenses and other current assets		(1,620	)		(2,499	)
Accounts payable and accrued liabilities		10,176			6,593
Accrued payroll and related expenses		(33,529	)		4,108
Income taxes		(3,625	)		(2,588	)
Net cash provided by operating activities		113,198			160,585
Investing activities:
Acquisitions and investments		—			(4,100	)
Proceeds from other investments		1,132			—
Purchases of intangible assets		(3,810	)		(7,501	)
Purchases of property and equipment		(77,857	)		(94,430	)
Purchases of marketable securities		(207,695	)		—
Net cash used in investing activities		(288,230	)		(106,031	)
Financing activities:
Proceeds from the issuance of common stock		3,871			3,888
Purchases of treasury stock		(79,680	)		(13,343	)
Payment of contingent consideration		(7,053	)		(809	)
Proceeds from issuance of convertible debt, net of issuance costs		873,890			—
Proceeds from sale of warrants		93,915			—
Purchases of convertible note hedges		(147,825	)		—
Other financing activities		(1,405	)		2,283
Net cash provided by (used in) financing activities		735,713			(7,981	)
Effect of exchange rate changes on cash		829			(1,014	)
Increase in cash, cash equivalents and restricted cash		561,510			45,559
Cash, cash equivalents and restricted cash at beginning of period		214,528			120,235
Cash, cash equivalents and restricted cash at end of period	$	776,038		$	165,794

###

Investor Contact:

Suzanne Hatcher

NuVasive, Inc.

858-458-2240

investorrelations@nuvasive.com

Media Contact:

Jessica Tieszen

NuVasive, Inc.

858-736-0364

media@nuvasive.com

XML

Document and Entity Information	Oct. 29, 2020
Cover [Abstract]
Entity Registrant Name	NuVasive, Inc.
Amendment Flag	false
Entity Central Index Key	0001142596
Document Type	8-K
Document Period End Date	Oct. 29, 2020
Entity Incorporation State Country Code	DE
Entity File Number	000-50744
Entity Tax Identification Number	33-0768598
Entity Address, Address Line One	7475 Lusk Boulevard
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	(858)
Local Phone Number	909-1800
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Security 12b Title	Common Stock, par value $0.001 per share
Trading Symbol	NUVA
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false